Literature DB >> 19276364

Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.

Pal Kaposi-Novak1, Louis Libbrecht, Hyun Goo Woo, Yun-Han Lee, Nathaniel C Sears, Cedric Coulouarn, Elizabeth A Conner, Valentina M Factor, Tania Roskams, Snorri S Thorgeirsson.   

Abstract

Hepatocarcinogenesis is a multistage process in which precursor lesions progress into early hepatocellular carcinomas (eHCC) by sequential accumulation of multiple genetic and epigenetic alterations. To decode the molecular events during early stages of liver carcinogenesis, we performed gene expression profiling on cirrhotic (regenerative) and dysplastic nodules (DN), as well as eHCC. Although considerable heterogeneity was observed at the regenerative and dysplastic stages, overall, 460 differentially expressed genes were detected between DN and eHCC. Functional analysis of the significant gene set identified the MYC oncogene as a plausible driver gene for malignant conversion of the DNs. In addition, gene set enrichment analysis revealed global activation of the MYC up-regulated gene set in eHCC versus dysplasia. Presence of the MYC signature significantly correlated with increased expression of CSN5, as well as with higher overall transcription rate of genes located in the 8q chromosome region. Furthermore, a classifier constructed from MYC target genes could robustly discriminate eHCC from high-grade and low-grade DNs. In conclusion, our study identified unique expression patterns associated with the transition of high-grade DNs into eHCC and showed that activation of the MYC transcription signature is strongly associated with the malignant conversion of preneoplastic liver lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276364      PMCID: PMC2680077          DOI: 10.1158/0008-5472.CAN-08-3357

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Making myc.

Authors:  J Liu; D Levens
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

2.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

Authors:  Ju-Seog Lee; Jeonghoon Heo; Louis Libbrecht; In-Sun Chu; Pal Kaposi-Novak; Diego F Calvisi; Arsen Mikaelyan; Lewis R Roberts; Anthony J Demetris; Zongtang Sun; Frederik Nevens; Tania Roskams; Snorri S Thorgeirsson
Journal:  Nat Med       Date:  2006-03-12       Impact factor: 53.440

3.  Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.

Authors:  Mohini A Patil; Ines Gütgemann; Ji Zhang; Coral Ho; Siu-Tim Cheung; David Ginzinger; Rui Li; Karl J Dykema; Samuel So; Sheung-Tat Fan; Sanjay Kakar; Kyle A Furge; Reinhard Büttner; Xin Chen
Journal:  Carcinogenesis       Date:  2005-07-06       Impact factor: 4.944

4.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

Authors:  Andrea H Bild; Guang Yao; Jeffrey T Chang; Quanli Wang; Anil Potti; Dawn Chasse; Mary-Beth Joshi; David Harpole; Johnathan M Lancaster; Andrew Berchuck; John A Olson; Jeffrey R Marks; Holly K Dressman; Mike West; Joseph R Nevins
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

5.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.

Authors:  Michael T Hemann; Anka Bric; Julie Teruya-Feldstein; Andreas Herbst; Jonas A Nilsson; Carlos Cordon-Cardo; John L Cleveland; William P Tansey; Scott W Lowe
Journal:  Nature       Date:  2005-08-11       Impact factor: 49.962

6.  Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling.

Authors:  Suk Woo Nam; Jik Young Park; Adaikalavan Ramasamy; Shirish Shevade; Amirul Islam; Philip M Long; Cheol Keun Park; Soo Eun Park; Su Young Kim; Sug Hyung Lee; Won Sang Park; Nam Jin Yoo; Edison T Liu; Lance D Miller; Jung Young Lee
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

7.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

Authors:  Pal Kaposi-Novak; Ju-Seog Lee; Luis Gòmez-Quiroz; Cédric Coulouarn; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

Review 8.  Imaging diagnosis.

Authors:  Riccardo Lencioni; Dania Cioni; Clotilde Della Pina; Laura Crocetti; Carlo Bartolozzi
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

9.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Elizabeth A Conner; Ju-Seog Lee; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

10.  Genetic regulators of large-scale transcriptional signatures in cancer.

Authors:  Adam S Adler; Meihong Lin; Hugo Horlings; Dimitry S A Nuyten; Marc J van de Vijver; Howard Y Chang
Journal:  Nat Genet       Date:  2006-03-05       Impact factor: 38.330

View more
  84 in total

Review 1.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

Review 2.  Stem cells in hepatocarcinogenesis: evidence from genomic data.

Authors:  Jens U Marquardt; Snorri S Thorgeirsson
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  Is hepatitis C virus carcinogenic?

Authors:  Stanley M Lemon; David R McGivern
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 4.  Hepatocellular carcinoma.

Authors:  Marie-Annick Buendia; Christine Neuveut
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-02       Impact factor: 6.915

5.  MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.

Authors:  Zhongwei Cao; Hua Fan-Minogue; David I Bellovin; Aleksey Yevtodiyenko; Julia Arzeno; Qiwei Yang; Sanjiv Sam Gambhir; Dean W Felsher
Journal:  Cancer Res       Date:  2011-01-24       Impact factor: 12.701

6.  Translation control of the immune checkpoint in cancer and its therapeutic targeting.

Authors:  Yichen Xu; Mauro Poggio; Hyun Yong Jin; Zhen Shi; Craig M Forester; Ying Wang; Craig R Stumpf; Lingru Xue; Emily Devericks; Lomon So; Hao G Nguyen; Alice Griselin; John D Gordan; Sarah E Umetsu; Siegfried H Reich; Stephen T Worland; Saurabh Asthana; Maria Barna; Kevin R Webster; John T Cunningham; Davide Ruggero
Journal:  Nat Med       Date:  2019-01-14       Impact factor: 53.440

Review 7.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

Review 8.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

9.  Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.

Authors:  Ágnes Holczbauer; Valentina M Factor; Jesper B Andersen; Jens U Marquardt; David E Kleiner; Chiara Raggi; Mitsuteru Kitade; Daekwan Seo; Hirofumi Akita; Marian E Durkin; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2013-03-19       Impact factor: 22.682

10.  Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma.

Authors:  Masato Tsuchiya; Joel S Parker; Hiroshi Kono; Masanori Matsuda; Hideki Fujii; Ivan Rusyn
Journal:  Mol Cancer       Date:  2010-04-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.